Common Bile Duct Obstruction

Common bile duct obstruction (CBDO) is a clinical syndrome characterized by partial or complete blockage of the common bile duct, the final conduit through which bile flows from the intrahepatic and extrahepatic biliary tree into the duodenum. This obstruction impedes the normal excretion of bile, leading to accumulation of bile acids, bilirubin, and other biliary constituents in the liver and systemic circulation. The condition is a major cause of extrahepatic cholestasis in dogs and cats, and if untreated, can rapidly progress to severe hepatic injury, biliary tract infection, coagulopathy, and life-threatening complications such as biliary rupture and bile peritonitis. CBDO can be classified based on the site of obstruction (intraluminal, mural, or extramural), the degree (partial vs. complete), and the chronicity (acute vs. chronic). The clinical presentation varies from subtle non-specific signs to acute abdomen and icterus, depending on the underlying cause and the rapidity of onset. Prompt recognition and intervention are critical to prevent irreversible hepatic damage and systemic sequelae.

The etiologies of common bile duct obstruction are diverse and can be categorized into intraluminal, mural, and extramural causes. Intraluminal obstructions are most commonly due to cholelithiasis (gallstones), inspissated bile (biliary sludge), or parasitic infections such as liver flukes (Platynosomum concinnum in cats, Fasciola hepatica in dogs). Mural obstructions arise from neoplasia of the bile duct epithelium (cholangiocarcinoma), inflammatory strictures secondary to chronic cholangitis, or trauma-induced fibrosis. Extramural obstructions are frequently caused by pancreatic diseases, particularly pancreatic neoplasia (adenocarcinoma) or severe pancreatitis with associated edema and fibrosis. Other extramural causes include abdominal masses (e.g., lymphadenopathy, hepatic tumors, intestinal masses), abscesses, granulomas, and diaphragmatic hernias. In cats, inflammatory bowel disease and triaditis (concurrent pancreatitis, cholangitis, and inflammatory bowel disease) are significant contributors. Additionally, iatrogenic causes such as surgical ligation or trauma during abdominal surgery can lead to obstruction. In some cases, the exact cause remains idiopathic. The underlying etiology significantly influences the clinical approach, diagnostic workup, and therapeutic strategy.

Common bile duct obstruction is a relatively uncommon but clinically important condition in small animal practice. It is more frequently diagnosed in dogs than in cats, although the exact incidence is not well documented. In dogs, middle-aged to older animals are more commonly affected, with a median age of around 8-10 years. Certain breeds may be predisposed to specific etiologies; for example, Miniature Schnauzers are predisposed to hyperlipidemia and pancreatitis, which can lead to extrahepatic obstruction. Shetland Sheepdogs and Cocker Spaniels have a higher incidence of cholelithiasis. In cats, cholangitis and triaditis are common underlying causes, and the condition may be seen in cats of any age, but middle-aged to older cats are more frequently affected. There is no strong sex predilection, though some studies suggest a slight female predominance in cats with biliary disease. Geographic variations exist, with liver fluke infections being more common in tropical and subtropical regions, such as the southeastern United States, Hawaii, and the Caribbean. The condition is not seasonal, but the incidence may reflect the prevalence of underlying diseases such as pancreatitis or neoplasia.

The pathophysiology of common bile duct obstruction involves a cascade of events initiated by the blockage of bile flow. Bile is continuously produced by hepatocytes and flows through the biliary tree into the gallbladder and then through the common bile duct to the duodenum. When obstruction occurs, intraductal pressure rises, leading to bile stasis and subsequent regurgitation of bile constituents into the hepatic parenchyma. This results in cholestasis, characterized by the accumulation of bilirubin, bile acids, and cholesterol in the blood and tissues. The increased pressure causes hepatocellular injury, initially affecting the biliary epithelium and later leading to hepatocyte necrosis and apoptosis. The retained bile acids are directly toxic to hepatocytes, causing cell membrane damage and mitochondrial dysfunction. Inflammatory mediators are released, attracting neutrophils and macrophages, which further exacerbate tissue injury. Chronic obstruction leads to bile duct proliferation, periportal fibrosis, and ultimately cirrhosis. The lack of bile in the intestine impairs fat digestion and absorption, leading to steatorrhea and deficiencies of fat-soluble vitamins (A, D, E, K). Vitamin K deficiency results in impaired synthesis of clotting factors II, VII, IX, and X, leading to coagulopathy. Additionally, the obstructed biliary tree is a favorable environment for bacterial overgrowth, increasing the risk of ascending cholangitis and sepsis. Systemic effects include endotoxemia, systemic inflammatory response syndrome (SIRS), and multi-organ dysfunction. If the obstruction is not relieved, the gallbladder and bile ducts may rupture, causing bile peritonitis, a severe and often fatal complication.

Several intrinsic and extrinsic factors predispose animals to common bile duct obstruction. Intrinsic factors include anatomical variations, such as a tortuous or narrow common bile duct, which may increase the risk of obstruction. Genetic predispositions are evident in certain breeds, such as Miniature Schnauzers with hyperlipidemia and a tendency for pancreatitis, and Shetland Sheepdogs with a higher incidence of cholelithiasis. Metabolic disorders, including hyperadrenocorticism, diabetes mellitus, and hypothyroidism, can alter bile composition and promote gallstone formation. Age is a risk factor, as older animals have a higher incidence of neoplasia and degenerative changes. Extrinsic factors include dietary influences, such as high-fat diets that may precipitate biliary sludge and gallstones. Obesity is a contributing factor to hyperlipidemia and pancreatitis. Concurrent diseases, particularly inflammatory bowel disease in cats, can lead to triaditis and subsequent biliary obstruction. Immunosuppressive therapy, such as corticosteroids, may increase susceptibility to infections, including cholangitis. Trauma to the abdomen can cause bile duct injury or stricture. Iatrogenic factors, such as surgical manipulation during abdominal procedures, can inadvertently damage the bile duct. Environmental factors, such as exposure to hepatotoxic substances, may also play a role. Understanding these predisposing factors is essential for risk assessment and preventive strategies.

The clinical signs of common bile duct obstruction vary depending on the degree and duration of obstruction, as well as the underlying cause. In peracute cases, animals may present with acute vomiting, abdominal pain, and collapse, often due to severe pancreatitis or rupture of the biliary tree. Acute obstruction typically manifests with icterus (jaundice), which is often the first noticeable sign, along with lethargy, anorexia, and vomiting. The urine may appear dark yellow to orange due to bilirubinuria, and the feces may become pale or clay-colored due to lack of bilirubin (acholic feces). Subacute and chronic obstructions may present with more insidious signs, including weight loss, intermittent vomiting, and progressive icterus. Some animals may develop signs of hepatic encephalopathy, such as behavioral changes, disorientation, and ptyalism, due to the accumulation of neurotoxins. Physical examination findings include icterus of the mucous membranes, sclera, and skin, which is best visualized in the pinnae, gingiva, and sclera. Abdominal palpation may reveal hepatomegaly, a distended gallbladder, or a painful abdomen, particularly if pancreatitis or cholecystitis is present. Fever may be present if cholangitis or sepsis has developed. In chronic cases, signs of coagulopathy, such as petechiae, ecchymoses, or prolonged bleeding from venipuncture sites, may be observed. Terminal stages may be characterized by severe lethargy, hypothermia, and shock.

The differential diagnoses for common bile duct obstruction include a wide range of conditions that cause icterus, vomiting, and abdominal pain. Key differentials include: 1) Hepatic disease: Acute or chronic hepatitis, cirrhosis, and hepatic neoplasia can cause icterus due to intrahepatic cholestasis. Laboratory findings may show elevated liver enzymes, but bilirubinuria and acholic feces are less common. 2) Hemolytic anemia: Immune-mediated hemolytic anemia (IMHA) or other causes of hemolysis can lead to prehepatic icterus. These patients typically have anemia, spherocytosis, and a positive Coombs test, with normal liver enzyme levels. 3) Pancreatitis: Severe pancreatitis can cause extrahepatic obstruction due to inflammation and edema of the pancreatic tissue surrounding the common bile duct. Clinical signs and laboratory findings may overlap, but imaging (ultrasound) and pancreatic-specific lipase (cPLI/fPLI) can help differentiate. 4) Cholecystitis: Inflammation of the gallbladder can cause biliary stasis and secondary obstruction. Ultrasound may show gallbladder wall thickening and biliary sludge. 5) Biliary mucocele: A mucocele is a sterile accumulation of mucus in the gallbladder that can obstruct the common bile duct. It is more common in dogs, particularly Shetland Sheepdogs and Cocker Spaniels. Ultrasound reveals a characteristic 'kiwi-like' appearance. 6) Cholangitis/cholangiohepatitis: In cats, lymphocytic or neutrophilic cholangitis can cause intrahepatic cholestasis and may be associated with triaditis. Liver biopsy is often needed for definitive diagnosis. 7) Neoplasia: Cholangiocarcinoma, pancreatic adenocarcinoma, or metastatic disease can cause obstruction. Imaging and cytology/histopathology are essential. 8) Intestinal obstruction: Foreign bodies or intussusception can cause vomiting and abdominal pain, but icterus is uncommon unless there is concurrent biliary obstruction. 9) Peritonitis: Bile peritonitis or septic peritonitis can cause acute abdomen and icterus. Abdominocentesis and fluid analysis are diagnostic. 10) Drug-induced hepatotoxicity: Certain drugs (e.g., acetaminophen, phenobarbital) can cause hepatic injury and cholestasis. A thorough drug history is important.

The diagnostic approach to common bile duct obstruction should be systematic and stepwise. 1) Initial assessment: Perform a thorough history and physical examination, with emphasis on icterus, abdominal pain, and palpable abdominal masses. 2) Baseline laboratory tests: Complete blood count (CBC), serum biochemistry profile, and urinalysis. Key findings include elevated bilirubin (total and direct), elevated liver enzymes (ALP, GGT, ALT, AST), and bilirubinuria. A CBC may show leukocytosis or left shift if infection is present. 3) Coagulation profile: Prothrombin time (PT) and activated partial thromboplastin time (aPTT) should be assessed due to the risk of vitamin K deficiency and coagulopathy. 4) Abdominal ultrasound: This is the imaging modality of choice. It can identify extrahepatic bile duct dilation, gallbladder distension, choleliths, biliary sludge, pancreatic masses, and hepatic changes. It can also guide fine-needle aspiration of the gallbladder or liver. 5) Additional imaging: If ultrasound is inconclusive, computed tomography (CT) or magnetic resonance cholangiopancreatography (MRCP) may be considered. 6) Specific biomarkers: Measurement of serum bile acids (fasting and postprandial) can confirm cholestasis. Pancreatic lipase immunoreactivity (cPLI/fPLI) is useful to rule out pancreatitis. 7) Cytology/histopathology: Fine-needle aspiration of the liver or gallbladder may be performed for cytology, but histopathology via biopsy is often needed for definitive diagnosis of underlying causes such as cholangitis or neoplasia. 8) Exploratory laparotomy: If the diagnosis remains uncertain or if surgical intervention is planned, exploratory laparotomy with biopsy and possible biliary diversion (e.g., cholecystoenterostomy) may be necessary. 9) Advanced diagnostics: In cases of suspected infectious causes, bile culture and sensitivity, PCR for infectious agents (e.g., Platynosomum), and serology may be performed. The diagnostic algorithm should be tailored to the individual patient, balancing invasiveness and cost with the need for a definitive diagnosis.

Laboratory findings in common bile duct obstruction reflect cholestasis, hepatocellular injury, and impaired synthetic function. Hematology: The CBC may be normal or show a stress leukogram. In cases of cholangitis or sepsis, neutrophilic leukocytosis with a left shift may be present. Anemia may be seen if there is concurrent hemolysis or chronic disease. Serum biochemistry: The most consistent finding is hyperbilirubinemia, with a predominance of conjugated (direct) bilirubin. Total bilirubin is typically >2 mg/dL, and direct bilirubin is >50% of the total. Alkaline phosphatase (ALP) is markedly elevated, often >1000 U/L, due to increased synthesis in response to cholestasis. Gamma-glutamyltransferase (GGT) is also elevated, and in cats, GGT may be more specific for cholestasis. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are elevated due to hepatocellular injury, but the degree of elevation is variable. Cholesterol and triglycerides may be elevated due to impaired lipid metabolism. Bile acids are significantly increased, both fasting and postprandial. Coagulation profile: Prothrombin time (PT) and activated partial thromboplastin time (aPTT) may be prolonged due to vitamin K deficiency, leading to decreased synthesis of clotting factors II, VII, IX, and X. Urinalysis: Bilirubinuria is present, often before icterus is clinically apparent. The urine specific gravity may be low if there is concurrent renal disease. Blood gas analysis: Metabolic acidosis may be present if there is concurrent sepsis or shock. Specific biomarkers: Serum pancreatic lipase immunoreactivity (cPLI for dogs, fPLI for cats) is elevated if pancreatitis is the underlying cause. C-reactive protein (CRP) may be elevated as an acute-phase protein. In cats, feline pancreatic lipase immunoreactivity (fPLI) is useful. Serology/PCR: For infectious causes, such as liver flukes, fecal examination or PCR may be performed. Endocrine assays: If hyperadrenocorticism is suspected, ACTH stimulation test or low-dose dexamethasone suppression test may be indicated.

Imaging plays a crucial role in the diagnosis and management of common bile duct obstruction. Abdominal radiography: Survey radiographs may show hepatomegaly, loss of abdominal detail, or a mass effect in the right cranial abdomen. However, radiographs are often unremarkable and are not sensitive for biliary obstruction. Abdominal ultrasonography: This is the primary imaging modality. Findings include dilation of the common bile duct (>5 mm in dogs, >4 mm in cats), distension of the gallbladder, and increased echogenicity of the bile due to sludge or choleliths. The gallbladder wall may be thickened or hyperechoic. The liver may show diffuse or nodular changes. Ultrasonography can also identify pancreatic masses, abdominal lymphadenopathy, and free abdominal fluid. Doppler ultrasound can assess blood flow in the portal vein and hepatic artery. Computed tomography (CT): CT provides more detailed anatomical information and is particularly useful for evaluating the pancreas and peri-pancreatic tissues. It can detect masses, calcifications, and ductal dilation. CT is also useful for surgical planning. Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP): These modalities provide high-resolution images of the biliary tree and pancreatic duct, and MRCP is non-invasive and can delineate the level of obstruction. Endoscopic retrograde cholangiopancreatography (ERCP) is rarely performed in veterinary medicine but can be used for both diagnosis and therapy. Fluoroscopy may be used during interventional procedures such as stent placement. Echocardiography is not directly relevant but may be performed to assess cardiac function if anesthesia is planned. The choice of imaging depends on availability, cost, and the patient's stability.

Cytology and histopathology are essential for determining the underlying cause of common bile duct obstruction. Fine-needle aspiration (FNA) of the liver can be performed percutaneously or under ultrasound guidance. Cytological findings may include cholestasis (bile pigment in hepatocytes and Kupffer cells), hepatocellular vacuolation, and inflammatory cells (neutrophils, lymphocytes, plasma cells) if cholangitis is present. FNA of the gallbladder may yield bile for culture and cytology, but this carries a risk of bile peritonitis if leakage occurs. Histopathology from liver biopsy is the gold standard for diagnosing cholangitis, cholangiohepatitis, cirrhosis, and neoplasia. In cholangitis, there is infiltration of inflammatory cells in the portal tracts, bile duct proliferation, and periportal fibrosis. In cholangiocarcinoma, there are malignant epithelial cells forming acinar structures. In cases of extrahepatic obstruction, the liver may show bile duct hyperplasia, portal edema, and bile infarcts. Special stains, such as Gram stain for bacteria, may be helpful. If a pancreatic mass is identified, FNA or biopsy of the pancreas may be performed. Histopathology of the gallbladder wall may reveal cholecystitis or mucocele. The results of cytology and histopathology guide treatment decisions, including the need for surgery and the choice of antimicrobials or immunosuppressive therapy.

The treatment of common bile duct obstruction depends on the underlying cause, the severity of clinical signs, and the presence of complications. Emergency stabilization is the first priority. Intravenous fluid therapy with balanced crystalloids (e.g., lactated Ringer's solution) is initiated to correct dehydration and electrolyte imbalances. If there is evidence of sepsis or SIRS, colloids or vasopressors may be needed. Analgesia is provided with opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV q8-12h, or fentanyl CRI at 2-5 mcg/kg/h). Antiemetics such as maropitant (1 mg/kg IV q24h) or ondansetron (0.5-1 mg/kg IV q12h) are administered if vomiting is present. Nutritional support is crucial; if the animal is anorexic, a feeding tube (nasoesophageal, esophagostomy, or gastrostomy) may be placed. Medical therapy includes the administration of vitamin K1 (0.5-1.5 mg/kg SC or IM q12h for 3-5 doses) to correct coagulopathy. Antibiotics are indicated if cholangitis or sepsis is suspected; choices include amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or enrofloxacin (5-10 mg/kg PO/IV q24h) combined with metronidazole (10-15 mg/kg PO q12h). Ursodeoxycholic acid (10-15 mg/kg PO q24h) may be used to promote bile flow and reduce hepatocyte injury. S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) is an antioxidant that may be beneficial. Definitive treatment often requires surgical intervention. Cholecystectomy is indicated for cholecystitis, mucocele, or neoplasia. Cholecystoenterostomy (e.g., cholecystoduodenostomy or cholecystojejunostomy) is performed to bypass an obstruction of the common bile duct. In cases of cholelithiasis, choledochotomy or choledochal stenting may be performed. In cats with triaditis, medical management of pancreatitis and inflammatory bowel disease is essential. Interventional radiology techniques, such as endoscopic or percutaneous stent placement, are being developed but are not widely available. Postoperative care includes continued fluid therapy, analgesia, antibiotics, and nutritional support. The underlying disease must be addressed to prevent recurrence.

The prognosis for common bile duct obstruction varies widely depending on the underlying cause, the duration of obstruction, and the presence of complications. In cases of acute obstruction due to cholelithiasis or biliary sludge, the prognosis is generally good if surgical intervention is performed promptly. The prognosis is guarded to poor if the obstruction is due to malignant neoplasia, such as cholangiocarcinoma or pancreatic adenocarcinoma, as these are often advanced at the time of diagnosis. Chronic obstruction can lead to irreversible hepatic fibrosis and cirrhosis, which carries a poor long-term prognosis. The development of bile peritonitis or septic cholangitis significantly worsens the prognosis, with mortality rates exceeding 50%. Coagulopathy, if not corrected, increases the risk of surgical complications. Negative prognostic indicators include marked hyperbilirubinemia (>10 mg/dL), prolonged PT/aPTT, hypoalbuminemia, and elevated creatinine. In cats, the prognosis is often guarded due to the high prevalence of triaditis and the difficulty in managing the underlying inflammatory conditions. However, with aggressive medical and surgical management, some animals can achieve long-term survival. Regular monitoring and management of underlying diseases are essential for a favorable outcome.

Follow-up care for common bile duct obstruction is critical to monitor recovery and detect complications. Immediately after surgery or medical stabilization, patients should be hospitalized for 2-5 days, with daily monitoring of vital parameters, hydration status, and urine output. Serial blood work, including liver enzymes, bilirubin, and coagulation parameters, should be performed every 24-48 hours until values are improving. Once discharged, recheck examinations are recommended at 1 week, 2 weeks, 1 month, and then every 3-6 months for the first year. At each recheck, a physical examination, CBC, serum biochemistry profile, and urinalysis should be performed. Liver enzyme activities and bilirubin should be monitored to ensure they are returning to normal. If the underlying cause was pancreatitis, serial fPLI or cPLI measurements may be useful. Imaging, such as abdominal ultrasound, should be repeated at 1 month and then as needed to assess for recurrence of obstruction or progression of underlying disease. If the patient is on long-term medications (e.g., ursodeoxycholic acid, SAMe, or immunosuppressive drugs), dose adjustments should be made based on clinical response and laboratory values. Owners should be educated on the signs of recurrence, such as icterus, vomiting, or lethargy, and advised to seek immediate veterinary care if these occur. Long-term management may include a low-fat diet, especially in dogs with hyperlipidemia or pancreatitis. In cats with inflammatory bowel disease, dietary modification and immunosuppressive therapy may be necessary. Regular dental care and parasite control are also important.

Clinical Pearls: 1) Icterus is often the first sign of common bile duct obstruction; however, it may not be visible until bilirubin exceeds 2 mg/dL. 2) ALP is markedly elevated in extrahepatic obstruction, often >1000 U/L, but can also be elevated in other conditions; GGT is more specific for cholestasis. 3) Vitamin K administration is crucial before any invasive procedure to prevent bleeding complications. 4) Abdominal ultrasound is the most valuable diagnostic tool; a dilated common bile duct (>5 mm in dogs) is a strong indicator of obstruction. 5) In cats, always consider triaditis (pancreatitis, cholangitis, and inflammatory bowel disease) as a cause of biliary obstruction. 6) Bile culture should be obtained during surgery to guide antibiotic therapy. 7) Early surgical intervention improves outcomes in cases of cholelithiasis or mucocele. 8) Ursodeoxycholic acid is beneficial in chronic cholestasis to reduce hepatocyte injury. 9) Monitor for hypoglycemia and sepsis in critically ill patients. 10) Consider the use of a feeding tube early to provide nutritional support. Clinical Pitfalls: 1) Do not delay surgery in cases of suspected biliary rupture or mucocele; these are emergencies. 2) Avoid the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with hepatic disease due to the risk of further injury. 3) Do not administer corticosteroids without a definitive diagnosis, as they may worsen infection or neoplasia. 4) Be cautious with the use of hepatotoxic drugs, such as acetaminophen, in any patient with liver disease. 5) Do not rely solely on radiography; it is insensitive for biliary obstruction. 6) Do not perform a liver biopsy without assessing coagulation status. 7) In cats, do not overlook the possibility of liver fluke infection; a fecal examination or PCR may be needed. 8) Do not assume that hyperbilirubinemia is always due to obstruction; hemolysis and hepatic disease must be ruled out. 9) Do not forget to monitor for postoperative complications such as bile peritonitis, pancreatitis, or stricture formation. 10) Do not discharge the patient without clear instructions for monitoring and follow-up.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current veterinary guidelines. 1) Fluid therapy: Lactated Ringer's solution or Normosol-R at a rate of 60-100 mL/kg/day IV, adjusted based on hydration status and ongoing losses. 2) Analgesia: Buprenorphine 0.01-0.02 mg/kg IV or IM q8-12h; or fentanyl CRI at 2-5 mcg/kg/h IV. 3) Antiemetics: Maropitant 1 mg/kg IV or SC q24h; or ondansetron 0.5-1 mg/kg IV q12h. 4) Vitamin K1: 0.5-1.5 mg/kg SC or IM q12h for 3-5 doses, then as needed based on coagulation parameters. 5) Antibiotics: Amoxicillin-clavulanate 12.5-25 mg/kg PO or IV q12h; enrofloxacin 5-10 mg/kg PO or IV q24h; metronidazole 10-15 mg/kg PO q12h. Combination therapy is often used for broad-spectrum coverage. 6) Ursodeoxycholic acid: 10-15 mg/kg PO q24h, preferably with food. 7) S-adenosylmethionine (SAMe): 20 mg/kg PO q24h on an empty stomach. 8) Hepatoprotectants: Silymarin (milk thistle) 20-50 mg/kg PO q24h may be used. 9) Nutritional support: If anorexic, consider a feeding tube; use a high-quality, easily digestible diet. 10) In cases of pancreatitis, additional therapy may include octreotide (not routinely recommended) or supportive care. 11) For cats with triaditis, immunosuppressive doses of prednisolone (1-2 mg/kg PO q24h) may be indicated, but only after ruling out infectious causes. 12) For hyperlipidemia, consider a low-fat diet and omega-3 fatty acids (eicosapentaenoic acid/docosahexaenoic acid 100-200 mg/kg PO q24h). 13) If coagulopathy is severe, fresh frozen plasma (10-20 mL/kg IV) may be administered. 14) In cases of septic shock, vasopressors such as norepinephrine (0.05-0.3 mcg/kg/min CRI) may be needed. 15) Always adjust dosages in patients with renal or hepatic impairment; for example, enrofloxacin should be used with caution in cats and may require dose reduction. 16) Monitor for drug interactions, especially with drugs that are hepatically metabolized.

Evidence-based literature on common bile duct obstruction in dogs and cats is limited but growing. A landmark study by Center et al. (1995) described the clinical and pathological features of extrahepatic biliary obstruction in dogs, highlighting the importance of early surgical intervention. A retrospective study by Mayhew et al. (2002) evaluated the outcomes of cholecystectomy in dogs with biliary mucocele, reporting a good prognosis with surgery. Another study by O'Neill et al. (2006) compared medical versus surgical management of cholelithiasis in dogs, finding that surgery was associated with a higher success rate. In cats, a study by Callahan Clark et al. (2011) investigated the association between cholangitis and inflammatory bowel disease, supporting the concept of triaditis. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of cholangitis in cats was published in 2016, providing guidelines for antimicrobial and immunosuppressive therapy. Regarding drug therapy, a randomized controlled trial by Webster et al. (2017) evaluated the efficacy of ursodeoxycholic acid in dogs with chronic hepatitis, showing improvement in liver enzyme activities. A study by Tamborini et al. (2016) assessed the use of S-adenosylmethionine in cats with cholangitis, demonstrating a reduction in oxidative stress markers. The use of vitamin K in cholestatic liver disease is well-established, with studies showing correction of coagulopathy. Overall, the evidence supports a multimodal approach, with surgery being the mainstay for mechanical obstruction, and medical therapy for underlying inflammatory or infectious causes. Further research is needed to establish standardized protocols and prognostic factors.